ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The l ...

ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The l ...

ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, ...

公司背景 - Clearside Biomedical, Inc.是一家生物制药公司，通过SCS®技术，革新了治疗眼部疾病的递送方式[3] - 公司的SCS注射平台利用专利的SCS Microinjector®，实现了一种在办公室内、可重复、非手术的程序，针对黄斑、视网膜或脉络膜进行有针对性和分隔式的治疗递送，可能有助于保护和改善患有威胁视力的眼部疾病的患者的视力[3] 产品信息 - 公司的主要项目CLS-AX（axitinib injectable suspension）用于治疗新生血管性年龄相关性黄斑变性（濕性AMD），目前正在进行2b期临床试验[3] - Clearside已经开发并获得了首个产品XIPERE®的批准，用于SCS途径，目前在美国通过商业合作伙伴提供[3]

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024. Dr. Chong is a board-certified retinal specialist with more than 25 years of experience as a retinal physician and navigating all phases of ophthalmic drug development. George Lasezkay ...

公司财务状况 - 公司现金及现金等价物总额约为2900万美元[5] - 完成了股票和认股权证的注册直接发行，募集了1500万美元的总收益[5] - 预计资金足以支持公司计划的运营至2025年第三季度[5] 业务发展 - 公司重点关注领域为完成湿性AMD的ODYSSEY Phase IIb临床试验，并计划在今年第三季度报告顶线数据[6] - 公司与合作伙伴在超脉络膜空间继续领先，展示药物输送的额外优势[6] - 公司致力于开发新治疗方法，与领先的医疗公司合作，改善患有威胁视力疾病的个体视力[6] 新产品研发 - 公司的Phase II试验为三个装载剂，与其他公司的试验设计有所不同[9] - TKI作为一组将成为湿性AMD患者治疗选择中非常重要的补充[12] - TKI具有延长持续时间的效果，与抗VEGFA机制非常协调[12] 治疗方案展望 - TKI的使用应该被视为湿性AMD的真正机会，而不是取代其他治疗方法[13] - 公司认为TKI和抗VEGFA的联合治疗对湿性AMD患者有益，患者将是这种联合治疗的主要受益者[13] 临床试验结果 - 公司对suprachoroidal注射的安全性表现非常好，与视网膜内注射相比并无明显差异[16] - 在OASIS试验中，一毫克剂量的患者需要更多的违背方案或早期救助，但在ODYSSEY试验中公司已采取措施以减少这种情况的发生[20] 市场扩张计划 - 公司目前专注于潮湿型AMD，暂无计划探索CLS-AX在DME或DR等其他适应症的使用[21] - 目前尚无关于XIPERE的销售量和销售额的数据，因为在销售额达到4500万美元之前，公司无法报告任何收入[24]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to __________ Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-2437375 (State ...

财务业绩 - Clearside Biomedical宣布2023年第四季度和全年财务业绩，并提供企业更新[1] - 第四季度许可和其他收入为6345万美元，较2022年第四季度的330万美元增长了6000万美元，主要归因于从BioCryst收到的500万美元的前期许可费和Aura Biosciences的100万美元里程碑付款[12][29] - 研发费用为2023年第四季度为630万美元，较2022年第四季度的500万美元增加了130万美元，主要是由于ODYSSEY临床试验成本[13][29] - 管理和行政费用为2023年第四季度为290万美元，较2022年第四季度的320万美元减少了30万美元，主要是由于保险费用降低和专利相关成本的时间安排[14][29] - 非现金利息费用为2023年第四季度为230万美元，较2022年第四季度的200万美元增加了30万美元，非现金利息费用包括对未来版税销售相关负债的计息和相关发行成本的摊销[15][29] - 2023年第四季度净亏损为480万美元，每股普通股亏损为0.08美元，较2022年第四季度的970万美元净亏损，每股普通股亏损为0.16美元减少[16][29] - 截至2023年12月31日，Clearside的现金及现金等价物总额为2890万美元，公司相信通过最新的股票和认股权证直接发行，将有足够的资源支持计划到2025年第三季度的运营[17][29]

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora ...

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora ...